NCPA Urges Key House Committees to Take Action on Medicare Generic Drug Payment Legislation

Published Online: Thursday, June 26, 2014
Follow Pharmacy_Times:
PRESS RELEASE

ALEXANDRIA, Va. (June 26, 2014) – In its efforts to advance the Generic Drug Pricing Transparency Act (H.R. 4437), the National Community Pharmacists Association (NCPA) is asking the leaders of the House Energy and Commerce Committee and House Ways and Means Committee to “closely examine and ultimately consider this common sense bipartisan legislation.”

In a letter to the panels’ Chairmen and Ranking Members, NCPA CEO B. Douglas Hoey, RPh, MBA wrote, “Even though pharmacists are reimbursed for generic prescriptions via Maximum Allowable Cost (MAC) lists, these lists are not updated on a regular basis which frequently results in pharmacists being reimbursed below their acquisition cost for various medications particularly in today’s pharmaceutical marketplace which has recently been plagued with a series of generic medication price spikes.”

Community pharmacies’ cost of acquiring many generic drugs has increased 1000% or more virtually overnight but MAC-based reimbursements from pharmacy benefit managers (PBMs) may remain outdated for months before PBMs update payment rates and rarely do so retroactively. That often leaves community pharmacies with unsustainable losses of $60 to $100 or more per prescription.

Hoey noted in the NCPA letter that the Centers for Medicare & Medicaid Services (CMS) partially addressed the concerns of community pharmacists in this area. A recently published final rule contains a provision that takes effect in 2016 and requires PBMs to disclose to pharmacies MAC rates and to update them every seven days.

While NCPA appreciates CMS’ action, H.R. 4437 would go further by implementing the following provisions:
  • First, the legislation would establish an appeals process for pharmacies to resolve disputes over outdated MAC limits.
  • Second, it would protect patient privacy by requiring the patient’s permission before the PBM could transmit personally identifiable utilization or claims data to a PBM-owned pharmacy.
  • Third it would protect patient choice by prohibiting a PBM from requiring that a beneficiary use a retail or mail order pharmacy in which the PBM has an ownership interest.

The legislation was introduced by Reps. Doug Collins (R-Ga.) and Dave Loebsack (D-Iowa). Legislation similar to H.R.4437 has been enacted on a bipartisan basis in 16 states over the past two years.
Related Articles
The National Community Pharmacists Association today praised a Medicare final regulation to discourage Medicare Part D prescription drug plans from paying long-term care pharmacies lower, prorated dispensing fees for "short-cycle" prescriptions.
Seniors would have more convenient access to discounted or "preferred" copays for prescription drugs at their pharmacy of choice under new bipartisan legislation introduced recently and endorsed today by the National Community Pharmacists Association.
The Corrective Action Plan that federal Medicare officials have requested of Aetna is an important first step and the Centers for Medicare & Medicaid Services should go one further by issuing new guidance to all Medicare Part D prescription drug plan sponsors to prevent a 2016 repeat of the Aetna problems experienced in early 2015.
Beneficiaries, CMS, Taxpayers would benefit from uniform approach.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$